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Type 2 diabetes mellitus (T2DM) and osteoporosis are asso-
ciated with severe morbidity, increased mortality, and impor-
tant social costs, mainly due to their chronic consequences
[1]. Epidemiological data indicates that T2DM is associated
with increased risk of fractures, suggesting that skeletal fra-
gility should be considered among the chronic complications
of T2DM [2, 3] and, in turn, T2DM should be considered
among the causes of endocrine osteoporosis [4].
A common feature of the endocrine forms of osteoporo-
sis is the reduced role of bone mineral density (BMD) in
predicting fragility fractures [4]. In fact, T2DM does not
represent an exception, since, even more than in the other
endocrine related osteoporosis forms, it is generally charac-
terised by normal or increased BMD [5]. As a consequence,
in T2DM, the risk of fracture is largely independent of
BMD, and the latter should not be considered a sensitive
enough index of bone fragility [6]. Indeed, if in the presence
of reduced BMD an increased risk of fracture has to be con-
sidered, then in the presence of normal BMD an increased
risk of fractures could not be excluded [5]. Therefore, the
fracture risk assessment algorithms, which are significantly
based on BMD, are not accurate enough for identifying
T2DM patients at risk for fractures [7, 8].
The simpler, but likely incomplete, explanation for the
lack of association between BMD and fracture risk in
T2DM is that in this endocrine form of osteoporosis reduced
bone quality rather than bone density is the main cause of
reduced bone strength [9]. This impaired bone quality can
be attributed to different mechanisms, whose knowledge
represents a challenge for researchers since this information
could be used to identify possible targets for both predicting
fractures and curing T2DM-related osteoporosis [10].
The reduced bone turnover and impairment of osteoblast
activity have been advocated among the possible mecha-
nisms underlying the reduction in bone quality in T2DM
[11, 12].
For this special issue, we received different scientific
contributions spanning from in vitro studies to animal and
clinical research articles.
The paper by Zhang et al., entitled “FOXO1 Mediates
Advanced Glycation End Products Induced Mouse
Osteocyte-Like MLO-Y4 Cell Apoptosis and Dysfunctions,”
explored the capacity of advanced glycation end products
(AGEs) to induce osteocyte apoptosis, thus impacting bone
homeostasis. Using mouse osteocyte-like MLO-Y4 cells,
the authors showed that FOXO1 plays a crucial role in
AGE-induced osteocyte dysfunction and apoptosis through
its regulation of caspase-3, sclerostin, and RANKL.
In the article by Mohsin et al., entitled “Type 2 Diabetes
Mellitus Increases the Risk to Hip Fracture in Postmeno-
pausal Osteoporosis by Deteriorating the Trabecular Bone
Microarchitecture and Bone Mass,” using a micro-CT, the
authors analysed the changes in the trabecular bone micro-
structure due to T2DM at various time points in ovariecto-
mised and nonovariectomised rats. Their data suggest that
T2DM negatively affects the trabecular structure of the fem-
oral heads of rats and that these changes are correlated with
the T2DM duration, increasing the risk of hip fractures.
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In the paper by Guo et al., entitled “Assessment of Risk
Factors for Fractures in Patients with Type 2 Diabetes over
60 Years Old: A Cross-Sectional Study from Northeast
China,” the authors investigated the prevalence of bone frac-
tures in elderly Chinese subjects (with and without T2DM)
and evaluated the risk factors for fractures. In particular,
when measuring the heel BMD and the timed “up and go”
(TUG), the authors observed that low BMD and slow TUG
times were independent risk factors for fractures in non-
T2DM patients, while no associations were found in the
T2DM population. Patients with T2DM had a higher risk
for fractures, even when they had preserved BMD and a
short TUG time. Therefore, the authors concluded that
TUG and BMD underestimated the risk of fractures in the
T2DM population.
The review by C. Eller-Vainicher et al., entitled “Patho-
physiology and Management of Type 2 Diabetes Mellitus
Bone Fragility,” summarised the complex pathophysiological
mechanisms underlying bone fragility in T2DM patients. In
the first part of the review, the authors analysed the correct
clinical approach for evaluating bone health in T2DM patients
beyond dual X-ray densitometry, with particular attention to
other imaging techniques that have been investigated in
recent years, such as trabecular bone score, hip structural
analysis, quantitative ultrasound, and peripheral quantitative
computed tomography. Moreover, the authors examined the
role of microindentation and bone turnover markers in the
evaluation of bone fragility in T2DM patients. The second
part of the review was dedicated to the factors that lead to
bone fragility in T2DM, from disease duration, insulin use,
glycometabolic control, and complications to the effects of
the different antidiabetic drugs on bone and other metabolic
aspects, such as obesity and cortisol secretion.
Finally, the article by Zhao et al., entitled “Association
between Uric Acid and Bone Mineral Density in Postmeno-
pausal Women with Type 2 Diabetes Mellitus in China-A
cross-sectional Inpatients Study,” retrospectively evaluated
the association between uric acid levels and BMD in 262
postmenopausal women with T2DM. The authors concluded
that uric acid levels were neither a protective factor nor a risk
factor for osteoporosis in these subjects.
We think that the articles in this special issue contribute
to increasing the knowledge of the pathogenesis of bone
fragility in T2DM patients and may be the starting point
for future research.
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